Abstract

Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the presence of drug. However, the incidence of KD mutations in imatinibnaive patients, irrespective of response to therapy, is unknown. We studied mutation frequency in 66 patients with chronic myelogenous leukemia (CML), using cDNA sequencing and allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR) assays for 8 common mutations. Thirteen patients were positive by ASO-PCR only, 1 by ASO-PCR and sequencing, and 1 by sequencing only (overall frequency, 22.7%). T315I was most frequent (12% of patients). Eleven of the 14 patients with positive ASO-PCR had follow-up samples available for sequencing. Wild-type sequence was detected in 6 of 11, 2 different mutations in 1 of 11, and identical mutations in 4 of 11 patients, 2 of whom had achieved major cytogenetic response. In multivariate analysis mutation detection was associated with clonal cytogenetic evolution, exposure to 6-Thioguanine, and a low platelet count, but not with response to imatinib, event-free survival, and overall survival. KD mutants present at low levels do not invariably lead to relapse, and additional factors are required to induce a fully drug-resistant phenotype. (Blood. 2005; 106:2128-2137)

Introduction

Imatinib is a highly effective therapy in all stages of chronic myelogenous leukemia (CML), but relapse after an initial response is common in patients with advanced disease.1-3  In 50% to 90% of patients with acquired resistance to imatinib, mutations in the kinase domain (KD) of BCR-ABL have been detected. These mutations result in impaired drug binding and are thought to cause clinical resistance.4-8  Although mutations have been identified in more than 20 different amino acids, the 8 most common mutations account for greater than 70% of cases.9  In some patients who relapsed with KD mutations, analysis of archived material stored prior to therapy revealed the identical nucleotide exchanges.5,10-12  In most of these cases the proportion of mutant allele was small, and detection required sensitive techniques, such as polymerase chain reaction with allele-specific oligonucleotides (ASO-PCR), but isolated cases with up to 40% of mutant allele were also reported.5  Overall, these data are consistent with selection of resistant clones in the presence of imatinib. The fact that some KD domain mutant clones expand to the level of detection even before initiation of therapy suggests that some mutations may confer a growth advantage even in the absence of imatinib. Such mutants would be gain-of-function over wild type and could thus contribute to disease progression. The available data from imatinib-naive samples are limited to patients in whom mutations were detected at the time of relapse, and the incidence of mutations prior to therapy in unselected patients has not been established. Furthermore, it is not known whether KD mutant clones that are detectable prior to therapy are regularly selected in the presence of imatinib, and whether they may predict for an adverse outcome on therapy. To address these questions, we analyzed the frequency of KD mutations in a cohort of imatinib-naive patients with CML in chronic phase, accelerated phase, or blast crisis. We used a panel of newly developed fluorescence-based allele-specific PCR assays for high-sensitivity detection of the most common mutations as well as conventional sequencing of PCR products amplified from cDNA. The detection of KD mutants was then correlated with baseline variables and outcome.

Patients, materials, and methods

Patients

Sixty-six patients with CML in first chronic phase (n = 20), accelerated phase (n = 27), and myeloid blast crisis (n = 19) were treated with imatinib within Novartis-sponsored multi-institutional trials approved by the Institutional Review Board of the University of Leipzig, Leipzig, Germany. Prior to the study, informed consent was obtained according to the Declaration of Helsinki. Patient characteristics are given in Table 1. Accelerated phase was defined as any of the following: basophils in the peripheral blood (PB) of at least 20%, blasts in PB or bone marrow (BM) greater than 15% but less than 30%, blasts plus promyelocytes in the PB greater than 30%, platelet count less than 100 × 109/L (unless related to therapy), or clonal cytogenetic abnormalities in addition to the Philadelphia chromosome. Blastic phase was diagnosed when the blast count in the BM or PB exceeded 30%. Patients with chronic phase received an initial dose of 400 mg imatinib daily, and patients with accelerated phase or blast crisis received 600 mg daily. Complete hematologic response (CHR), partial hematological response (PHR), and major cytogenetic response (MCR) were defined according to published response criteria.1,2,13  The patients were routinely followed by peripheral blood counts and clinical examinations at 2- to 4-week intervals. Cytogenetics and quantitative reverse transcription (RT)-PCR14  were done every 3 to 6 months.

Table 1.

Patient characteristics


Characteristic
 

Data
 
Sex, no. (%)  
Female   38 (57.6)  
Male   28 (42.4)  
Age, y, median (range)   57 (31-80)  
Disease duration, mo, median (range)   30 (0-190)  
Disease phase, no. (%)  
Chronic   20 (30.3)  
Accelerated   27 (40.1)  
Clonal cytogenetic evolution only   10 (15.2)  
Blastic   19 (28.8)  
Clonal cytogenetic evolution, no. (%)†  26 (39.3)  
Prior therapy, no. (%)  
Hydroxyurea   51 (77.3)  
Interferon-α   37 (56.1)  
Cytarabine   18 (27.3)  
Topoisomerase II inhibitors   11 (16.7)  
6-Mercaptopurine   6 (9.1)  
6-Thioguanine   6 (9.1)  
Busulfan   5 (7.8)  
Melphalan   3 (4.5)  
Other*  4 (6.1)  
None
 
4 (6.1)
 

Characteristic
 

Data
 
Sex, no. (%)  
Female   38 (57.6)  
Male   28 (42.4)  
Age, y, median (range)   57 (31-80)  
Disease duration, mo, median (range)   30 (0-190)  
Disease phase, no. (%)  
Chronic   20 (30.3)  
Accelerated   27 (40.1)  
Clonal cytogenetic evolution only   10 (15.2)  
Blastic   19 (28.8)  
Clonal cytogenetic evolution, no. (%)†  26 (39.3)  
Prior therapy, no. (%)  
Hydroxyurea   51 (77.3)  
Interferon-α   37 (56.1)  
Cytarabine   18 (27.3)  
Topoisomerase II inhibitors   11 (16.7)  
6-Mercaptopurine   6 (9.1)  
6-Thioguanine   6 (9.1)  
Busulfan   5 (7.8)  
Melphalan   3 (4.5)  
Other*  4 (6.1)  
None
 
4 (6.1)
 
*

Includes vincristine (1 patient), fludarabine (1), splenic radiotherapy (1), and total-body irradiation before allografting (1).

Data available for 62 of 66 patients.

Cell lines

BaF3 cells expressing the Q252H, Y253F, Y253H, E255K, E255V, T315I, M351T, and F359V mutants of p210BCR-ABL have been described or were generated accordingly.7,15,16  The CML cell line K562 was used as a positive control for wild-type BCR-ABL, while HL60 cells were used as negative control. All cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum and penicillin and streptomycin.

Allele-specific real-time PCR

RNA was extracted with affinity columns (RNAeasy kit, Qiagen, Hilden, Germany) from 5 to 10 × 106 nucleated bone marrow cells isolated by red cell lysis. cDNA was synthesized with random hexamer primers in 40-μL reactions, as described.17 ABL was amplified as a quality control for the cDNA preparation.17 

Conditions for allele-specific PCR amplification of the 8 most common BCR-ABL mutants were optimized on an MJ Research Opticon 2 System (MJ Research, Reno, NV). PCR amplification was performed in a single step using 1 of 2 universal 5′ primers located on BCR exon 13 and individual allele-specific 3′ primers (Table 1). Fluorescence was detected by SybrGreen (Applied Biosystems, Foster City, CA). For optimization of conditions, serial dilutions of mutant plasmid DNA in distilled water were used as well as cDNA prepared from serial dilutions of RNA from BaF3 cells expressing mutant BCR-ABL into RNA from BaF3 cells expressing wild-type BCR-ABL. Preliminary experiments showed that the sensitivity of the assay could be increased by 1:10 dilution of the cDNA. The precise reason for this phenomenon is unknown, although similar observations were made for ultrasensitive BCR-ABL amplification for detection of BCR-ABL mRNA in healthy individuals.18  Assays were deemed acceptable if they (1) detected mutant BCR-ABL with a sensitivity of at least 1:103 in cell lines (RNA from BaF3 cells expressing mutant BCR-ABL diluted in RNA from BaF3 cells expressing wild-type BCR-ABL), (2) consistently showed no amplification of wild-type only and BCR-ABL-negative controls after 45 (Q252H, Y253F, Y253H, E255K) or 50 cycles (E255V, T315I, M351T, F359V) of PCR, and (3) generated PCR products with a consistent melting curve in all positive control reactions.12 

Patient samples were tested twice in triplicate 20-μL reactions for all 8 mutations. Each reaction contained 1 × SybrGreen Master Mix (Applied Biosystems), 20 pmol each primer, 0.5 × PCR Enhancer (Invitrogen, Carlsbad, CA), and 2 μL diluted cDNA (equivalent to 2.5-5 × 104 cells, respectively). cDNA equivalent to at least 1.5 × 105 cells was screened for each of the 8 mutations. In each individual experiment, the sensitivity was monitored by amplification in duplicate of a serial dilution of mutant plasmid DNA. Strict precautions were taken to avoid false-positive results. The RNA extraction and cDNA synthesis were performed in a diagnostic laboratory (Leipzig, Germany) that had never handled recombinant mutant BCR-ABL. All reagents, including primers and water, pipette tips, tubes, and pipettors were new and exclusively used for this study. The reaction mixes were prepared, and patient samples were added in a “BCR-ABL-naive” laboratory located in a separate building at Oregon Health and Science University. The plates were sealed over the patient reactions and transported to the investigators' laboratory, where the controls were added to an unsealed portion of the plate. Negative controls (all in duplicate) included HL60 and K562 cells as well as no template tubes. Samples were scored positive, when all of the following criteria were met: (1) at least 1 of 3 wells positive in at least 1 of 2 assays, (2) amplification detected at least 3 cycles before the maximum cycle number of the assay (ie, at no more than 42 cycles for Q252H, Y253F, Y253H, E255K and at no more than 47 cycles for E255V, T315I, M351T, F359V), (3) shape of the melting curve identical to control (to avoid that fluorescence from nonspecific amplification products was scored as a true positive), (d) no specific amplification in any of the BCR-ABL wild-type or BCR-ABL-negative controls.

Mutation analysis by sequencing of PCR products

Patient cDNA was PCR amplified using B2A forward (TTCAGAAGCTTCTCCCTGACAT) and Abl 4065 reverse (CCTTCTCTAGCAGCTCATACACCTG). One microliter of this reaction was used as template in the nested reaction using Bcr F4 forward (ACAGCATTCCGCTGACCATCAATA) and U396 reverse (GCCATAGGTAGCAATTTCCC). All PCRs were performed with Accuprime polymerase (Invitrogen). PCR products were sequenced with both forward primer 3306F (TGGTTCATCATCATTCAACGG) and reverse primer 4000R (GGACATGCCATAGGTAGCA). Sequences were aligned and analyzed with Sequencher sequence analysis software (Gene Codes, Ann Arbor, MI).

Statistical analysis

We analyzed a number of pretreatment characteristics for association with the detection of KD mutations, hematologic response, or MCR, including sex, age (≤ 60 years, > 60 years), disease duration (≤ 12 months, > 12 months), therapy prior to imatinib, disease phase, clonal cytogenetic evolution (CE), splenomegaly, hemoglobin level (≤ 100 g/L, > 100 g/L), white blood cell count (≤ 10 × 109/L, > 10 × 109/L), platelet count (≤ 100 × 109/L, >100 × 109/L but ≤ 450 × 109/L, > 450 × 109/L), blasts in PB (≤ 7%, > 7%), basophils in the PB (≤ 7%, > 7%), blasts in BM (≤ 5%, > 5%). Data were analyzed by univariate logistic regression analysis with all pretreatment characteristics treated as independent variables. For the multivariate logistic regression, the stepwise procedure was used to identify pretreatment characteristics for KD mutation, PHR, or MCR among pretreatment characteristics with a P value less than .1 from univariate logistic regression. Only patients with complete data sets were included in the multivariate model. Event-free survival was defined as the interval from starting imatinib therapy to loss of PHR, CHR, or MCR, whichever occurred first, to initiation of alternative treatment or to death. Patients who underwent allogeneic stem cell transplantation without fulfilling any of these criteria were censored at the time of the allograft. Overall survival was defined as the interval between starting imatinib and death, regardless of the time of discontinuation of imatinib. Patients who underwent allografting were censored at the time of transplantation. Patients who discontinued imatinib because of toxicity or unrelated causes before progression had occurred were excluded from the analysis of event-free survival and overall survival.

Results

Establishment of allele-specific PCR assays for detection of KD mutations.

Because the purpose of our study was to screen for KD mutations with high sensitivity, we chose ASO-PCR as the screening strategy. ASO-PCR has been reported to achieve a sensitivity of up to 1 copy of mutant allele in 104 copies of wild-type allele.19  However, given that a separate assay, performed in multiple replicates, is required to test for each of the mutations, the number of different mutations included in the screening had to be limited. At least 28 different kinase domain mutations have been reported in patients with resistance to imatinib.4-8,15,16,20-22  From these, we selected mutations based on their prevalence in published series. Initial experiments were carried out to optimize the sensitivity and specificity of ASO-PCR for each of the selected mutations. Evaluation of primers designed to amplify ABL versus a combination of primers on BCR with the mutant ABL reverse primer showed the latter to be more specific. Attempts to use nested PCR to increase sensitivity led to loss of specificity, with detection of signals in wild-type BCR-ABL specimens (not shown). Eventually, optimal results were achieved with a 1-step approach using 1 of 2 universal 5′ primers on BCR exon 13 in conjunction with allele-specific primers complementary to the respective mutations on ABL. In several instances, the primer design included additional mismatches in the ABL primer to suppress amplification of wild-type allele. The melting curves of the amplification products were routinely compared with the melting curves of the simultaneously amplified standards, and only reactions with identical melting curves were scored positive (Figure 1). Overall, we established assays with a sensitivity of at least 1:103 for 8 common mutations, representing approximately 72% of clinical isolates.9  For 7 of these mutations, the sensitivity was reproducibly more than 105, while it was lower for Y253H (≥ 103) (Table 2).

Table 2.

Primer sequences, PCR conditions, and sensitivity of the ASO-PCR assays used in this study


Mutant
 

Base exchange
 

Frequency, %*
 

Primer names
 

Sequence (5′ → 3′)
 

Annealing temperature, °C
 

No. cycles
 

Product length, bp
 

Extension time, s
 

Detection limit, mutant/wild type
 
Q252H   G-C   5.1   252H C3R   TCGTACACCTCCCCGCAG   60.0   45   789   60   ≤ 1/100 000  
    Bcr 2687F   CGCTGACCATCAATAAGG       
Y253F   A-T   3.4   253F R   CTCGTACACCTCCCCGA   60.0   45   790   60   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
Y253H   T-C   6.8   253H 16R   CGTACACCTCCCCGTG   60.4   45   805   60   ≤ 1/1000  
    Bcr 2671F   ACTCCAGACTGTCCACAGCAT       
E255K   G-A   19.2   255K T3R   CACGCCCTCGTACACTTT   60.0   45   798   60   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
E255V   A-T   2.3   255V T3R   ACACGCCCTCGTACATCA   60.0   45   797   60   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
T315I   C-T   20.9   315 R   CGTAGGTCATGAACTCAA   60.0   50   994   80   ≤ 1/100 000  
    Bcr2671F   ACTCCAGACTGTCCACAGCAT       
M351T   T-C   15.3   351 G3R   TCTTCTCCAGGTACTGCG   60.0   50   1085   90   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
F359V   T-G   4.0   359 R   AAGATCTCTGTGGATGAC   60.0   50   1107   90   ≤ 1/100 000  

 

 

 
Bcr2687F
 
CGCTGACCATCAATAAGG
 

 

 

 

 

 

Mutant
 

Base exchange
 

Frequency, %*
 

Primer names
 

Sequence (5′ → 3′)
 

Annealing temperature, °C
 

No. cycles
 

Product length, bp
 

Extension time, s
 

Detection limit, mutant/wild type
 
Q252H   G-C   5.1   252H C3R   TCGTACACCTCCCCGCAG   60.0   45   789   60   ≤ 1/100 000  
    Bcr 2687F   CGCTGACCATCAATAAGG       
Y253F   A-T   3.4   253F R   CTCGTACACCTCCCCGA   60.0   45   790   60   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
Y253H   T-C   6.8   253H 16R   CGTACACCTCCCCGTG   60.4   45   805   60   ≤ 1/1000  
    Bcr 2671F   ACTCCAGACTGTCCACAGCAT       
E255K   G-A   19.2   255K T3R   CACGCCCTCGTACACTTT   60.0   45   798   60   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
E255V   A-T   2.3   255V T3R   ACACGCCCTCGTACATCA   60.0   45   797   60   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
T315I   C-T   20.9   315 R   CGTAGGTCATGAACTCAA   60.0   50   994   80   ≤ 1/100 000  
    Bcr2671F   ACTCCAGACTGTCCACAGCAT       
M351T   T-C   15.3   351 G3R   TCTTCTCCAGGTACTGCG   60.0   50   1085   90   ≤ 1/100 000  
    Bcr2687F   CGCTGACCATCAATAAGG       
F359V   T-G   4.0   359 R   AAGATCTCTGTGGATGAC   60.0   50   1107   90   ≤ 1/100 000  

 

 

 
Bcr2687F
 
CGCTGACCATCAATAAGG
 

 

 

 

 

 

The last nucleotide of the reverse primer matches the mutated base. Additional mismatches versus wild type are in bold and underlined.

*

N = 177.9

KD mutations are detectable in patients with CML in accelerated phase or blast crisis but not in chronic phase

Pretherapeutic samples from 66 patients were analyzed for all 8 mutations. These 66 patients consisted of 20 patients in first chronic phase, 27 in accelerated phase, and 19 in myeloid blast crisis, all previously untreated with imatinib. Mutations were detected by ASO-PCR in 14 (21.2%) of 66 patients. T315I was detected in 8 patients and was thus the most frequently detected mutation (12.1% of all samples). The Y253H mutant was detected in 2 patients. Q252H, as well as F359V, was seen in 1 patient each. In contrast, the E255V, E255K, and M351T mutations were not detected (Table 3). In most cases, the mutations were detected only at high cycle numbers, and only a fraction of the replicate reactions was positive (Table 4). This is consistent with low levels of mutant allele.

Table 3.

Frequency and types of mutations detected according to disease phase



 

Accelerated phase, no. (%)
 

Myeloid blast crisis, no. (%)
 

Total, no. (%)
 
No. patients   27   19   NA  
Q252H   1   0   1 (1.5)  
Y253F   1   1   2 (3.0)  
Y253H   1   1   2 (3.0)  
E255K   0   0   0 (0)  
E255V   0   0   0 (0)  
T315I   7   1   8 (12.1)  
M351T   0   0   0 (0)  
F359V   0   1   1 (1.5)  
V289I*  0   1   1 (1.5)  
Total (% of patients)
 
10 (37.0)
 
5 (23.8)
 
NA
 


 

Accelerated phase, no. (%)
 

Myeloid blast crisis, no. (%)
 

Total, no. (%)
 
No. patients   27   19   NA  
Q252H   1   0   1 (1.5)  
Y253F   1   1   2 (3.0)  
Y253H   1   1   2 (3.0)  
E255K   0   0   0 (0)  
E255V   0   0   0 (0)  
T315I   7   1   8 (12.1)  
M351T   0   0   0 (0)  
F359V   0   1   1 (1.5)  
V289I*  0   1   1 (1.5)  
Total (% of patients)
 
10 (37.0)
 
5 (23.8)
 
NA
 

No mutations were detected in the 20 patients with chronic-phase disease.

NA indicates not applicable

*

This mutation was not included in the ASO-PCR assay and was detected by sequencing.

Table 4.

Details on patients with detection of kinase domain mutations


Patient no.
 

Disease phase
 

Therapy prior to imatinib
 

Karyotype
 

Mutation by ASO-PCR
 

Ct mut
 

Positive reactions, no./total
 

Sequencing
 

Best response
 

Follow-up sequencing/disease status
 

Last follow-up/disease status
 
7   AP   IFN   46,XY,t(9,22)[18]; 47,XY,t(9;22), +der(22)[6];47, XY,+8[1]   T3151   45.8   1/6   WT   CHR   WT day +42/PHR; WT day +107/PHR;WT day +785/CHR   Alive in CHR day +1591  
13   AP   HU   46,XY,t(9;22)[24]/47,XY,t(9;22), +der(22)[1]   Q252H   35.6-40.4   3/6   WT   MCR (20% Ph+)   Q252H day +176/MCR; Q252H+F359V day +325/MCR   Alive in MCR day +1087  
17   AP   IFN, HU   46,XY,t(9;22)(q34; q11)[25]   T3151   46.9   1/6   WT   PHR   WT day + 80/PHR; WT day+270/PHR; WT day +444/hematologic relapse   Hematologic relapse day + 531; lost to follow-up  
25   AP   HU   46,XX,add(6)(p25), t(9;22)(q34;q11) [20]   T3151   46.7   1/6   WT   CHR   E255K+M351T day +365/CHR   Allogeneic transplant day +512 for lack of MCR  
29   AP   HU, IFN   45X-Y,t(9;22) (q34;q11)   Y253H   40.2   1/6   WT   mCR (52% Ph+)   WT day +85/CHR; WT day +267/CHR   Hematologic relapse day +452; lost to follow-up  
36   AP   HU, IFN, 6-TG   47,XY,t(9;22) (q34;q11),+der(22) [23];46,XY,t(9;22) (q34;q11)[1]   T3151   46.6-47.9   2/6   K247R   CHR   K247R day +107/CHR   Hematologic relapse day +212; alive day +1011  
41   AP   none   46,XX,t(9;22) (q34;q11),−der(22), +idic der (22)[12]   T3151   43.7   1/6   WT   CCR   T3151 day +93/CCR; T3151 day +182/CCR   Alive in molecular remission day + 1009  
42   AP   IDA, ARA-C, IFN   48,XY,+8,t(9; 22)(q34;q11),+der (22)t(9;22)(q34; q11)[8]   T3151   44.1-45.7   2/6   WT   CCR   WT day+193/CCR   Alive in CCR day +661  
45   AP   HU, 6-TG   44,XX,t(9;22)(q34; q11),der(14q+), t(17;18)(p11;q12?), −18,−20[23]   Y253F   38.2   1/6   WT   NA   ND   Died day +9 from sepsis  
46   AP   HU, 6-TG   46,XX,t(9;22)[10]   T3151   37.92-41.68   2/6   WT   CHR   T3151 day +158/hematologic relapse   Hematologic relapse + 158; died day + 1350 from progressive disease  
48   BC   HU, IFN   47,XX,+8,t(9; 22)(q34;11) [16],46,XX,t(9; 22)[4]   T3151   45.6   1/6   WT   NR   T3151 day +19/continuous blast crisis   Allogeneic transplant day + 140 for progressive disease; died from TRM  
55   BC   HU   ND   F359V   39.4-44.8   5/6   F359V   NR   ND   Died day + 18 from progressive disease  
59   BC   IFN, HU, 6-TG, MEL   57,XY,+1,+4, +6,+8,t(9;22) (q34;q11),+10,+11, +16,+18,+19,+21, +der2 2[5]   Y253F   41.2   1/6   WT   NR   ND   Died day +35 from progressive disease  
62   BC   IFN, HU   45,XY,t(9;22)(q34; q11),del(10)(p13?), −13[26]   Y253H   36.2   1/6   WT   NR   WT day +92/continuous blast crisis   Died day +208 from progressive disease  
56
 
BC
 
IFN, ARA-C
 
46,XY,t(9;22) (q34;q11)[15]
 
ND
 
NA
 
NA
 
V2891
 
NR
 
ND
 
Died day + 105 from progressive disease
 

Patient no.
 

Disease phase
 

Therapy prior to imatinib
 

Karyotype
 

Mutation by ASO-PCR
 

Ct mut
 

Positive reactions, no./total
 

Sequencing
 

Best response
 

Follow-up sequencing/disease status
 

Last follow-up/disease status
 
7   AP   IFN   46,XY,t(9,22)[18]; 47,XY,t(9;22), +der(22)[6];47, XY,+8[1]   T3151   45.8   1/6   WT   CHR   WT day +42/PHR; WT day +107/PHR;WT day +785/CHR   Alive in CHR day +1591  
13   AP   HU   46,XY,t(9;22)[24]/47,XY,t(9;22), +der(22)[1]   Q252H   35.6-40.4   3/6   WT   MCR (20% Ph+)   Q252H day +176/MCR; Q252H+F359V day +325/MCR   Alive in MCR day +1087  
17   AP   IFN, HU   46,XY,t(9;22)(q34; q11)[25]   T3151   46.9   1/6   WT   PHR   WT day + 80/PHR; WT day+270/PHR; WT day +444/hematologic relapse   Hematologic relapse day + 531; lost to follow-up  
25   AP   HU   46,XX,add(6)(p25), t(9;22)(q34;q11) [20]   T3151   46.7   1/6   WT   CHR   E255K+M351T day +365/CHR   Allogeneic transplant day +512 for lack of MCR  
29   AP   HU, IFN   45X-Y,t(9;22) (q34;q11)   Y253H   40.2   1/6   WT   mCR (52% Ph+)   WT day +85/CHR; WT day +267/CHR   Hematologic relapse day +452; lost to follow-up  
36   AP   HU, IFN, 6-TG   47,XY,t(9;22) (q34;q11),+der(22) [23];46,XY,t(9;22) (q34;q11)[1]   T3151   46.6-47.9   2/6   K247R   CHR   K247R day +107/CHR   Hematologic relapse day +212; alive day +1011  
41   AP   none   46,XX,t(9;22) (q34;q11),−der(22), +idic der (22)[12]   T3151   43.7   1/6   WT   CCR   T3151 day +93/CCR; T3151 day +182/CCR   Alive in molecular remission day + 1009  
42   AP   IDA, ARA-C, IFN   48,XY,+8,t(9; 22)(q34;q11),+der (22)t(9;22)(q34; q11)[8]   T3151   44.1-45.7   2/6   WT   CCR   WT day+193/CCR   Alive in CCR day +661  
45   AP   HU, 6-TG   44,XX,t(9;22)(q34; q11),der(14q+), t(17;18)(p11;q12?), −18,−20[23]   Y253F   38.2   1/6   WT   NA   ND   Died day +9 from sepsis  
46   AP   HU, 6-TG   46,XX,t(9;22)[10]   T3151   37.92-41.68   2/6   WT   CHR   T3151 day +158/hematologic relapse   Hematologic relapse + 158; died day + 1350 from progressive disease  
48   BC   HU, IFN   47,XX,+8,t(9; 22)(q34;11) [16],46,XX,t(9; 22)[4]   T3151   45.6   1/6   WT   NR   T3151 day +19/continuous blast crisis   Allogeneic transplant day + 140 for progressive disease; died from TRM  
55   BC   HU   ND   F359V   39.4-44.8   5/6   F359V   NR   ND   Died day + 18 from progressive disease  
59   BC   IFN, HU, 6-TG, MEL   57,XY,+1,+4, +6,+8,t(9;22) (q34;q11),+10,+11, +16,+18,+19,+21, +der2 2[5]   Y253F   41.2   1/6   WT   NR   ND   Died day +35 from progressive disease  
62   BC   IFN, HU   45,XY,t(9;22)(q34; q11),del(10)(p13?), −13[26]   Y253H   36.2   1/6   WT   NR   WT day +92/continuous blast crisis   Died day +208 from progressive disease  
56
 
BC
 
IFN, ARA-C
 
46,XY,t(9;22) (q34;q11)[15]
 
ND
 
NA
 
NA
 
V2891
 
NR
 
ND
 
Died day + 105 from progressive disease
 

Note that K247R is a previously unreported polymorphism.

Ct mut indicates PCR cycle at which mutant signal was detected; AP, accelerated phase; IFN, interferon-α; WT, wild type; CHR, complete hematologic response; PHR, partial hematologic response; HU, hydroxyurea; MCR, major cytogenetic response; mCR, minor cytogenetic response; 6-TG, 6-thioguanine; CCR, complete cytogenetic response; IDA, idarubicin; ARA-C, cytarabine; NA, not applicable; ND, not done; BC, blast crisis; NR, no response; TRM, transplant-related mortality; MEL, melphalan.

Figure 1.

Fluorescent ASO-specific PCR assay. RNA was extracted from a dilution of BaF3 cells expressing the T315I mutant of BCR-ABL in K562 cells, reversely transcribed into cDNA, and subjected to fluorescent ASO-specific PCR with primers optimized for detection of the T315I mutant. Plasmid DNA was included as a positive control. (A) Detection of amplification products by SybrGreen. 1 indicates plasmid DNA (control); 2 to 5, dilutions from 1:0 to 1:103; and 6, dilutions of 1:104 and 1:105 (curves overlap). (B) Melting curve analysis. Only selected melting curves are shown, and the colors do not correspond to panel A. 1 indicates curves corresponding to dilutions of 1:10, 1:103, and 1:105; 2, dilution of 1:106; and 3, K562 cells. (C) The PCR products of the fluorescent assay were run on a 1% agarose gel. Lane 1 indicates molecular weight marker; DNA, diluted plasmid DNA. Note the absence of PCR product in the 1:106 dilution and the K562-only specimen. The quality of cDNA was routinely checked by amplification of ABL as a control gene (not shown).

Figure 1.

Fluorescent ASO-specific PCR assay. RNA was extracted from a dilution of BaF3 cells expressing the T315I mutant of BCR-ABL in K562 cells, reversely transcribed into cDNA, and subjected to fluorescent ASO-specific PCR with primers optimized for detection of the T315I mutant. Plasmid DNA was included as a positive control. (A) Detection of amplification products by SybrGreen. 1 indicates plasmid DNA (control); 2 to 5, dilutions from 1:0 to 1:103; and 6, dilutions of 1:104 and 1:105 (curves overlap). (B) Melting curve analysis. Only selected melting curves are shown, and the colors do not correspond to panel A. 1 indicates curves corresponding to dilutions of 1:10, 1:103, and 1:105; 2, dilution of 1:106; and 3, K562 cells. (C) The PCR products of the fluorescent assay were run on a 1% agarose gel. Lane 1 indicates molecular weight marker; DNA, diluted plasmid DNA. Note the absence of PCR product in the 1:106 dilution and the K562-only specimen. The quality of cDNA was routinely checked by amplification of ABL as a control gene (not shown).

We also determined the rate of mutations detectable by conventional sequencing. In our hands, sequencing reliably detects mutations if at least 20% to 30% of the amplicon is mutant.23  Sixty-five samples (98.5%) were successfully amplified and gave high-quality readings. One patient (no. 55) was found to have a F359V mutation, confirming the results of the ASO-PCR assay, and 1 patient (no. 56) was found to have V289I, which is not included in the ASO-PCR assays. To our knowledge, the V289I mutation has not yet been described in patients, but V289S has been found in an in vitro mutagenesis screen for imatinib-resistant mutants, where it conferred a moderate level of drug resistance. In 2 additional patients (no. 8, no. 36) K247R was detected, and wild-type allele was completely absent. The K247R amino acid exchange has not previously been reported and appears to represent a rare polymorphism (L.C., unpublished observations, 2005). All other samples were wild type.

Overall (ie, ASO-PCR and conventional sequencing combined) mutations were detected in 10 (37.0%) of 27 patients with accelerated phase and 5 (26.3%) of 19 patients with blast crisis. None of the patients in chronic phase tested positive (Table 2). The Fisher exact test was used to compare mutation detection between patients with chronic phase, accelerated phase, and blast crisis. Mutations were detected at higher frequency in blast crisis phase versus chronic phase (P = .020) and accelerated phase versus chronic phase (P = .002). There was no difference between accelerated phase and blast crisis (P = .532).

Response to imatinib in patients with mutations

Fifteen patients had evidence for KD mutations, 2 of whom tested positive by sequencing, indicating a high proportion of mutant allele. One patient (no. 45) died from urosepsis on day +9 and was thus not evaluable for response.

Patients with imatinib-refractory disease

Five patients were refractory to imatinib, all were in myeloid blast crisis. Both patients (no. 55 with F359V and no. 56 with V289I) with mutations detected by sequencing died of progressive disease on day +35 and day +105, respectively. No follow-up samples were available for sequencing. In patient no. 48 (positive for T315I by ASO-PCR) T315I was detected by sequencing on day +19. She received salvage chemotherapy and eventually died of complications of allogeneic stem cell transplantation. Patients no. 59 (positive for Y253F by ASO-PCR) and no. 62 (positive for Y253H by ASO-PCR) died of progressive disease on day +35 and day +208, respectively. In patient no. 59, no follow-up specimens were available for sequencing, whereas only wild-type sequence was detected in patient no. 62 (day +92).

Patients with imatinib-responsive disease

Best responses to imatinib in the remaining 9 patients were PHR in 1, CHR in 5, and MCR in 3. In 5 patients sequencing of follow-up samples failed to detect mutations, including 4 patients with CHR or PHR (nos. 7, 17, 29, 36) and 1 with MCR (no. 42). Two of these 5 patients subsequently relapsed on days +212 (no. 36) and +444 (no. 17), and no mutations were detected at the time of disease recurrence. In 1 patient (no. 46) the T315I mutations detected by ASO-PCR prior to the treatment was detected by sequencing at the time of relapse. Patient no. 25 (positive for T315I by ASO-PCR) was positive by sequencing for E255K and M351T on day +365, while in CHR. She subsequently underwent allogeneic stem cell transplantation. In patients nos. 13 and 41, the mutation identified by ASO-PCR prior to therapy was detected by sequencing at the time of MCR (Figure 2). Patient no. 41 achieved CCR at 3 months and was in complete molecular response at last follow-up on day +1003. Sequencing revealed a mix of wild type and T315I at 3 months and 100% T315I at 6 months. Patient no. 13 achieved a partial cytogenetic response (20% Philadelphia chromosome [Ph]-positive metaphases) and an almost 2-log reduction of BCR-ABL transcripts (2.3% of pretherapeutic levels) at 6 months, while sequencing showed 100% Q252H. At 11 months, his BCR-ABL levels rose to 16.5% of pretherapeutic levels, while he continued to be in MCR (20% Ph-positive). Sequencing showed an F359V mutation in addition to Q252H. This evolution is most consistent with emergence of F359V in a separate cell clone that may have caused the rise in BCR-ABL mRNA.

Figure 2.

Follow-up of patients no. 13 and no. 41. (A) Patient no. 41. (Top) Sequence analysis of PCR products on days -7, +93, and +183 of imatinib therapy. ASO-PCR detected T315I on day -7, while conventional sequencing was negative. A mix of T315I and wild type (arrow) was detected on day +93, the time of first documented complete cytogenetic response. On day +183, only T315I was detected, while the patient remained in complete cytogenetic remission. (Bottom) Follow-up with quantitative and qualitative RT-PCR showed a gradual although not uninterrupted decrease of BCR-ABL transcripts and eventually complete molecular remission. (B) Patient no. 13. (Top) Sequence analysis of PCR products on days -18, +175, and +316 of imatinib therapy. ASO-PCR detected Q252H in the specimen from day -18. One hundred percent Q252H was detected on day +175 (left chromatogram, arrow). On day +326, a mix of Q252H and F359V was detected (arrows). Note that a small wild-type signal has reemerged in position 252. (Bottom) Follow-up with quantitative RT-PCR for BCR-ABL.

Figure 2.

Follow-up of patients no. 13 and no. 41. (A) Patient no. 41. (Top) Sequence analysis of PCR products on days -7, +93, and +183 of imatinib therapy. ASO-PCR detected T315I on day -7, while conventional sequencing was negative. A mix of T315I and wild type (arrow) was detected on day +93, the time of first documented complete cytogenetic response. On day +183, only T315I was detected, while the patient remained in complete cytogenetic remission. (Bottom) Follow-up with quantitative and qualitative RT-PCR showed a gradual although not uninterrupted decrease of BCR-ABL transcripts and eventually complete molecular remission. (B) Patient no. 13. (Top) Sequence analysis of PCR products on days -18, +175, and +316 of imatinib therapy. ASO-PCR detected Q252H in the specimen from day -18. One hundred percent Q252H was detected on day +175 (left chromatogram, arrow). On day +326, a mix of Q252H and F359V was detected (arrows). Note that a small wild-type signal has reemerged in position 252. (Bottom) Follow-up with quantitative RT-PCR for BCR-ABL.

Detection of KD mutations is associated with clonal cytogenetic evolution, low platelet count, and prior therapy with 6-Thioguanine but not with event-free or overall survival

A number of baseline disease characteristics were tested for their association with detection of mutations prior to therapy (Table 5). In univariate analysis, clonal cytogenetic evolution, disease phase, a low platelet count (compared with patients with normal platelet count), age older than 60 years, and previous therapy with 6-thioguanine (but not other cytotoxic drugs) were associated with mutation detection at P less than .1. These factors were then analyzed in a multivariate stepwise logistic regression model. Here, clonal cytogenetic evolution (estimated odds ratio [OR], 14.163), a low platelet count (estimated OR, 19.7), and prior treatment with 6-thioguanine (estimated OR, 43.3) retained statistical significance. It should be noted that all 3 associations have wide confidence intervals, particularly the association with 6-thioguanine (Table 5). No unusual pattern of clonal evolution was noted in patients with KD mutations, an additional Ph (Philadelphia chromosome) being the most frequent finding.

Table 5.

Analysis of factors for association with mutation detection


Factor
 

No. subjects
 

Mutation, no.
 

Univariate P
 

Multivariate P (n = 60)
 

Estimated odds ratio
 

95% Wald confidence interval
 
Sex       
Male   38   10   420   NA   NA   NA  
Female   28   5      
Age*       
60 y or younger   39   6   093   NS   NA   NA  
Older than 60 y   27   9      
Disease duration       
12 mo or fewer   17   2   211   NA   NA   NA  
Longer than 12 mo   48   13      
Prior therapy       
None, HU, IFN   35   9   593   NA   NA   NA  
Others   31   6      
Prior treatment with 6-thioguanine*       
Yes   6   4   018   006   43.295   2.916-642.928  
No   60   11      
Phase*       
Chronic   20   0   003   NS   NA   NA  
Accelerated + blastic   46   15      
Clonal evolution*       
Yes   26   11   003   006   14.163   2.083-96.316  
No   36   3      
Splenomegaly       
Yes   46   14   127   NA   NA   NA  
No   13   1      
Hemoglobin level       
More than 100 g/L   26   7   548   NA   NA   NA  
Less than 100 g/L   39   8      
White blood cell count       
More than 10 × 109/L   19   2   148   NA   NA   NA  
Fewer than 10 × 109/L   47   13      
Platelets ()*‡       
Fewer than 100 × 109/L   17   8   013   007   19.682   2.160-179.361  
At least 100 × 109/L but fewer than 450 × 109/L   30   4      
At least 450 × 109/L   17   3      
Blasts in PB       
5% or less   43   11   563   NA   NA   NA  
More than 5%   21   4      
Basophils in PB       
7% or less   43   12   122   NA   NA   NA  
More than 7%   20   2      
Blasts in BM       
5% or less   30   6   401   NA   NA   NA  
More than 5%
 
27
 
8
 

 

 

 

 

Factor
 

No. subjects
 

Mutation, no.
 

Univariate P
 

Multivariate P (n = 60)
 

Estimated odds ratio
 

95% Wald confidence interval
 
Sex       
Male   38   10   420   NA   NA   NA  
Female   28   5      
Age*       
60 y or younger   39   6   093   NS   NA   NA  
Older than 60 y   27   9      
Disease duration       
12 mo or fewer   17   2   211   NA   NA   NA  
Longer than 12 mo   48   13      
Prior therapy       
None, HU, IFN   35   9   593   NA   NA   NA  
Others   31   6      
Prior treatment with 6-thioguanine*       
Yes   6   4   018   006   43.295   2.916-642.928  
No   60   11      
Phase*       
Chronic   20   0   003   NS   NA   NA  
Accelerated + blastic   46   15      
Clonal evolution*       
Yes   26   11   003   006   14.163   2.083-96.316  
No   36   3      
Splenomegaly       
Yes   46   14   127   NA   NA   NA  
No   13   1      
Hemoglobin level       
More than 100 g/L   26   7   548   NA   NA   NA  
Less than 100 g/L   39   8      
White blood cell count       
More than 10 × 109/L   19   2   148   NA   NA   NA  
Fewer than 10 × 109/L   47   13      
Platelets ()*‡       
Fewer than 100 × 109/L   17   8   013   007   19.682   2.160-179.361  
At least 100 × 109/L but fewer than 450 × 109/L   30   4      
At least 450 × 109/L   17   3      
Blasts in PB       
5% or less   43   11   563   NA   NA   NA  
More than 5%   21   4      
Basophils in PB       
7% or less   43   12   122   NA   NA   NA  
More than 7%   20   2      
Blasts in BM       
5% or less   30   6   401   NA   NA   NA  
More than 5%
 
27
 
8
 

 

 

 

 

NS indicates not significant; PB, peripheral blood; BM, bone marrow; and NA, not applicable.

*

Factors with P < .1 in univariate analysis were included in the multivariate model.

Other antileukemic therapies were also analyzed individually for their effect on mutation frequency, but no significant associations were detected.

Significant only for comparison between platelets fewer than 100 and platelets of at least 100 but fewer than 450 (normal range).

We hypothesized that mutant clones, even if present only at low levels, may be rapidly selected in the presence of imatinib. Thus, patients with detectable mutations may relapse more rapidly than patients without mutations and may have a shorter survival. Three patients were excluded from this analysis, because of early death (neutropenic sepsis and urosepsis, respectively) or early discontinuation of imatinib for skin toxicity. In the remaining 63 cases, no association was found between mutation detection and hematologic response or major cytogenetic response, while the adverse effect of established prognostic factors such as advanced disease phase was confirmed (Tables 6 and 7). Consistent with the lack of a correlation between mutation detection and these endpoints, we did not find a correlation between mutation detection and event-free (P = .596) and overall (P = .560) survival in a univariate cox regression model (Figure 3A-B).

Table 6.

Analysis of baseline variables for their impact on hematologic response


Factors
 

No. subjects
 

No. subjects with hematologic response
 

Univariate P
 

Multivariate P(n = 56)
 
Sex     
Male   38   28   .179   NA  
Female   25   22    
Age*     
Younger than 60 y   38   33   .078   NA  
Older than 60 y   25   17    
Disease duration     
Fewer than 12 mo   16   14   .426   NA  
Longer than 12 mo   46   36    
Prior therapy     
None, HU, IFN   35   30   .170   NA  
Others   28   20    
Prior 6- Thioguanine     
Yes   58   46   .971   NA  
No   5   4    
Phase*     
Chronic   20   20   .005   NS  
Accelerated + blastic   43   30    
Clonal evolution*†     
Yes   25   16   .016   .010  
No   34   31    
Splenomegaly     
Yes   43   35   .772   NA  
No   13   10    
Hemoglobin level*     
At least 100 g/L   24   15   .016   NS  
Less than 100 g/L   38   34    
White blood cell count     
At least 10 × 109/L   19   16   .543   NA  
Fewer than 10 × 109/L   44   34    
Platelet count*     
No more than 100 × 109/L   16   9   .095   NS  
More than 100 × 109/L but less than 450 × 109/L   28   24    
More than 450   17   14    
Blasts in PB*‡     
5% or less   41   38   <.001   .001  
Greater than 5%   20   10    
Basophils in PB     
7% or less   42   32   .540   NA  
Greater than 7%   18   15    
Blasts in BM     
5% or less   29   29   .942   NA  
Greater than 5%   25   15    
Mutation     
Yes   14   9   .123   NA  
No
 
49
 
41
 

 

 

Factors
 

No. subjects
 

No. subjects with hematologic response
 

Univariate P
 

Multivariate P(n = 56)
 
Sex     
Male   38   28   .179   NA  
Female   25   22    
Age*     
Younger than 60 y   38   33   .078   NA  
Older than 60 y   25   17    
Disease duration     
Fewer than 12 mo   16   14   .426   NA  
Longer than 12 mo   46   36    
Prior therapy     
None, HU, IFN   35   30   .170   NA  
Others   28   20    
Prior 6- Thioguanine     
Yes   58   46   .971   NA  
No   5   4    
Phase*     
Chronic   20   20   .005   NS  
Accelerated + blastic   43   30    
Clonal evolution*†     
Yes   25   16   .016   .010  
No   34   31    
Splenomegaly     
Yes   43   35   .772   NA  
No   13   10    
Hemoglobin level*     
At least 100 g/L   24   15   .016   NS  
Less than 100 g/L   38   34    
White blood cell count     
At least 10 × 109/L   19   16   .543   NA  
Fewer than 10 × 109/L   44   34    
Platelet count*     
No more than 100 × 109/L   16   9   .095   NS  
More than 100 × 109/L but less than 450 × 109/L   28   24    
More than 450   17   14    
Blasts in PB*‡     
5% or less   41   38   <.001   .001  
Greater than 5%   20   10    
Basophils in PB     
7% or less   42   32   .540   NA  
Greater than 7%   18   15    
Blasts in BM     
5% or less   29   29   .942   NA  
Greater than 5%   25   15    
Mutation     
Yes   14   9   .123   NA  
No
 
49
 
41
 

 

 

NS indicates not significant; NA, not available.

*

Factors with P < .1 in univariate analysis were included in the multivariate model.

Estimated odds ratio = .086; 95% Wald confidence interval = 0.013-0.568.

Estimated odds ratio = .050; 95% Wald confidence interval = 0.008-0.322.

Table 7.

Analysis of baseline variables for their effect on major cytogenetic response


Factors
 

No. subjects
 

No. subjects with major cytogenetic response
 

Univariate P
 

Multivariate P(n = 48)
 
Sex     
Male   37   9   .107   NA  
Female   25   11    
Age     
Younger than 60 y   37   14   .256   NA  
Older than 60 y   25   6    
Disease*duration     
Fewer than 12 mo   16   9   .024   NS  
Longer than 12 mo   45   11    
Prior therapy*†     
None, HU, IFN   35   17   .003   .037  
Others   27   3    
Prior treatment with 6-thioguanine     
No   57   20   .971   NA  
Yes   5   0    
Phase*     
Chronic   20   13   <.001   NS  
Accelerated + blastic   42   7    
Clonal evolution*     
Yes   24   4   .082   NA  
No   34   13    
Splenomegaly     
Yes   43   16   .435   NA  
No   12   3    
Hemoglobin level*     
More than 100 g/L   24   2   .005   NS  
Less than 100 g/L   37   17    
White blood cell count*     
More than 10 × 109/L   19   9   .095   NS  
Fewer than 10 × 109/L   43   11    
Platelet count     
100 × 109/L or fewer   16   5   >.99   NA  
More than 100 × 109/L but less than 450 × 109/L   28   10    
More than 450 × 109/L   16   5    
Blasts (PB)     
5% or less   40   20   .940   NA  
More than 5%   20   0    
Basophils (PB)     
7% or less   41   14   .951   NA  
More than 7%   18   6    
Blasts (BM)*‡     
5% or less   28   16   .001   .0146  
More than 5%   25   3    
Mutation     
Yes   14   3   .330   NA  
No
 
48
 
17
 

 

 

Factors
 

No. subjects
 

No. subjects with major cytogenetic response
 

Univariate P
 

Multivariate P(n = 48)
 
Sex     
Male   37   9   .107   NA  
Female   25   11    
Age     
Younger than 60 y   37   14   .256   NA  
Older than 60 y   25   6    
Disease*duration     
Fewer than 12 mo   16   9   .024   NS  
Longer than 12 mo   45   11    
Prior therapy*†     
None, HU, IFN   35   17   .003   .037  
Others   27   3    
Prior treatment with 6-thioguanine     
No   57   20   .971   NA  
Yes   5   0    
Phase*     
Chronic   20   13   <.001   NS  
Accelerated + blastic   42   7    
Clonal evolution*     
Yes   24   4   .082   NA  
No   34   13    
Splenomegaly     
Yes   43   16   .435   NA  
No   12   3    
Hemoglobin level*     
More than 100 g/L   24   2   .005   NS  
Less than 100 g/L   37   17    
White blood cell count*     
More than 10 × 109/L   19   9   .095   NS  
Fewer than 10 × 109/L   43   11    
Platelet count     
100 × 109/L or fewer   16   5   >.99   NA  
More than 100 × 109/L but less than 450 × 109/L   28   10    
More than 450 × 109/L   16   5    
Blasts (PB)     
5% or less   40   20   .940   NA  
More than 5%   20   0    
Basophils (PB)     
7% or less   41   14   .951   NA  
More than 7%   18   6    
Blasts (BM)*‡     
5% or less   28   16   .001   .0146  
More than 5%   25   3    
Mutation     
Yes   14   3   .330   NA  
No
 
48
 
17
 

 

 

NS indicates not significant; NA, not available.

*

Factors with P < .1 in univariate analysis were included in the multivariate model.

Estimated odds ratio = 0.195; 95% Wald confidence interval = 0.042-0.912.

Estimated odds ratio = 0.150; 95% Wald confidence interval = 0.033-0.688.

Discussion

Using a highly sensitive and specific assay, we show that KD mutations are detectable in a substantial fraction of patients with imatinib-naive CML with advanced phase disease. As mutations were detected by conventional sequencing in only 2 cases (including one mutation that is not represented in the panel of ASO-PCR assays), we interpret this to mean that the proportion of mutant allele is usually low. In fact, detection of the signals by ASO-PCR usually required more than 40 PCR cycles, corresponding to less than 0.1% mutant cells as estimated by limiting dilution experiments using BaF3 cells expressing mutant BCR-ABL diluted in K562 cells. As repeated experiments demonstrated that at low concentrations of mutant allele these assays are not quantitative (Figure 1A; data not shown), it is impossible to estimate the proportion of KD mutant cells with greater precision.

In multivariate analysis, low platelet counts, clonal cytogenetic evolution, and prior exposure to 6-thioguanine were associated with mutation detection. It should be noted that clonal evolution was one of the defining criteria for accelerated phase, and that a relatively large proportion (37%) of the patients in accelerated phase had clonal evolution as the only diagnostic feature establishing a diagnosis of accelerated phase. The correlation between clonal evolution and mutation detection suggests that a common underlying mechanism may lead to an increased risk of additional cytogenetic abnormalities as well as point mutations. Bcr-Abl-expressing cells exhibit increased levels of reactive oxygen species that are thought to induce DNA damage.24  Bcr-Abl kinase activity appears to promote various mechanisms of DNA repair, However, the repair is frequently unfaithful, which is thought to be the result of defects in S phase25  and G2/M checkpoints,26  in combination with the antiapoptotic effects of Bcr-Abl.27  In this scenario, DNA repair occurs in situations that would normally induce an apoptosis response, leading to the accumulation of mutations.28  Notably, we also found a significant association between mutation detection and exposure to 6-Thioguanine, a drug that is mutagenic because of mispairing with thymine after incorporation into DNA,29  while patients with exposure to other cytotoxic drugs, including cytarabine and topoisomerase II inhibitors, were not at increased risk. Because the number of patients exposed to 6-Thioguanine was small, this finding should be interpreted with caution. Nonetheless it is plausible that patients with CML exposed to drugs with the potential to induce point mutations may be at higher risk of acquiring KD mutations, a factor that needs to be taken into account in the design of drug combination studies.

Several case reports and small studies described the detection of KD mutations in material stored prior to therapy.10-12,30  As these studies looked specifically for mutations that had been detected at the time of drug resistance, these findings are consistent with selection of resistant clones in the presence of imatinib. Two of our patients (no. 46 and no. 48) fit in this category. In both cases, the mutation detected prior to imatinib therapy became dominant at the time of relapse. However, in 2 other patients (no. 13 and no. 41) the mutations detected prior to therapy by ASO-PCR were found by sequencing at the time of partial and complete cytogenetic response. Patient no. 41 has maintained CCR for several years and was in complete molecular response at last follow-up on day +1009. In patient no. 13, Q252H was detected at 6 months, when he had achieved MCR (20% Ph-positive). At 11 months, MCR was maintained but a rise in BCR-ABL transcripts was apparent. At this time sequencing revealed a F359V mutation in addition to the preexisting Q252H, strongly suggesting the F359V had emerged in a different leukemic cell clone. It is conceivable that in both cases the mutant clone became detectable by the less-sensitive direct-sequencing technique because wild-type Bcr-Abl had been mostly eliminated by imatinib therapy. However, the mutant clones clearly failed to expand. This unexpected observation may have several reasons. First, it is possible that mutations occur in cell clones that have limited self-renewal capacity. Such clones, although at a proliferative advantage over wild type in the presence of imatinib, would not be able to sustain leukemic hematopoiesis long term. This would be in analogy to the observation that BCR-ABL transcripts are detectable in a substantial fraction of healthy individuals, most of whom will never develop CML.18  Second, the presence of a mutation alone may not be sufficient to confer a fully resistant phenotype in the absence of additional mechanisms. For example, the expression level of Bcr-Abl protein may not be sufficient to afford at least partial independence from exogenous cytokines, a phenomenon that has been described in Bcr-Abl-positive cell lines.31  Such cell clones, although Bcr-Abl positive, may not be able to compete against normal hematopoiesis. The same phenomena may account for the fact that in several patients sequencing of follow-up samples detected only wild-type sequence or (in patient no. 25) mutations that had not been detected by ASO-PCR and may explain why mutation detection was neither correlated with hematologic or cytogenetic response nor with overall or event-free survival. Thus, an important conclusion from our experiments is that high-sensitivity screening of imatinib-naive patients for KD mutations cannot be recommended, because it is impossible to predict whether the mutant clone will expand and cause relapse. In contrast, both patients (nos. 55 and 56) in whom the mutant clone was detected by sequencing in pretherapeutic samples did not respond to imatinib and died rapidly of progressive disease. The presence of mutant clones at high levels (detectable by sequencing) indicates that they were able to maintain leukemic hematopoiesis. This suggests that mutant clones detectable by sequencing in either imatinib-naive patients or patients with a rising disease burden on imatinib therapy have demonstrated the ability to sustain hematopoiesis and are almost invariably associated with subsequent relapse.32,33 

Figure 3.

Outcomes of patients on imatinib therapy. (A) Event free survival and (B) overall survival according to detection of kinase domain mutations prior to imatinib therapy. Censored patients indicated by triangles.

Figure 3.

Outcomes of patients on imatinib therapy. (A) Event free survival and (B) overall survival according to detection of kinase domain mutations prior to imatinib therapy. Censored patients indicated by triangles.

We are fully aware of the fact that a negative result, even with an extremely sensitive assay, does not exclude the presence of mutant clones below the level of detection. In addition, the ASO-PCR assays do not cover approximately one fourth of clinically isolated mutations.9  Not unexpectedly, a mutation not included in the ASO-PCR assays was detected in one patient. Therefore, it is possible that the frequency of positive calls would increase with more sensitive assays covering more types of mutations. Unfortunately, attempts to improve sensitivity by a nested PCR strategy were not successful, because of an unacceptable loss of specificity. The other concern is false-positive results. Although, in lieu of an alternative assay with comparable sensitivity, one cannot exclude false-positive results with certainty, it should be noted that extraordinary precautions were taken to avoid contamination by mutant BCR-ABL, and stringent criteria were applied to the interpretation of results. In addition, the strong correlation between mutation detection and biologic features such as clonal evolution and disease phase argues against false-positives results.

It is unclear why we detected certain mutations much more frequently than others. This is particularly obvious for the E255K and M351T mutations that account for 15% and 17% of clinical isolates.9  In both cases, limiting dilution experiments showed that the sensitivity of the assays was comparable to T315I, the most frequently detected mutation in our study. Given the relatively small numbers, these differences may be a chance finding. On the other hand, it is also possible that some mutations alter the biology of Bcr-Abl irrespective of their sensitivity to imatinib. In this scenario, mutants that are gain-of-function compared with wild type would be more likely to expand to the level of detection in the absence of imatinib than mutants that have a loss-of-function phenotype. For example, the M351T mutation appears to reduce Bcr-Abl kinase activity and transforming capacity compared with wild-type Bcr-Abl,34  which would explain why we failed to detect this mutation in any of our patients. Conversely, mutations that increase the transformation potency of BCR-ABL may represent a novel mechanism of disease progression. It must be stressed though that the numbers in this study are small; thus, results should not be overinterpreted.

In summary, we show that mutations of the BCR-ABL kinase domain are detectable in a fraction of imatinib-naive patients with advanced but not with chronic phase CML, and that their presence is correlated with clonal cytogenetic evolution, a low platelet count, and exposure to 6-Thioguanine. The fact that imatinib-resistant mutant clones present at low levels prior to therapy may disappear during treatment indicates that screening for mutations with highly sensitive assays may not be useful, at least in imatinib-naive patients. To adequately interpret the results of KD mutation analysis, the size of the mutant clone and the clinical context must be taken into account.

Prepublished online as Blood First Edition Paper, May 24, 2005; DOI 10.1182/blood-2005-03-1036.

Supported by grants from the Doris Duke Charitable Foundation (B.J.D.) and the Leukemia and Lymphoma Society (B.J.D.).

S.G.W. developed and performed the ASO-PCR assays, did part of the sequencing, and helped draft the manuscript; T.L. organized the generation of cDNA from imatinib-naive patients; S.D. helped with the construction of the KD mutant constructs; S.O. collected and organized the patient information; L.C. helped with sequencing; D.N. helped with collection of clinical patient information; E.P.S. helped with sequence analysis and manuscript preparation; S.McW. and B.P. did the statistical analysis; I.K. did the RNA extraction and cDNA synthesis; B.J.D. contributed to the design of this study; and M.W.D. developed the concept of the study, supervised the establishment of the ASO-PCR assay, and finalized the manuscript.

An Inside Blood analysis of this article appears in the front of this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

M.W.D. is a Junior Faculty Scholar of the American Society of Hematology.

1
Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blood.
2002
;
99
:
3530
-3539.
2
Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood.
2002
;
99
:
1928
-1937.
3
Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood.
2002
;
100
:
1965
-1971.
4
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Science.
2001
;
293
:
876
-880.
5
Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer Cell.
2002
;
2
:
117
-125.
6
Al Ali HK, Heinrich MC, Lange T, et al. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Hematol J.
2004
;
5
:
55
-60.
7
Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia.
2002
;
16
:
2190
-2196.
8
von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
Lancet.
2002
;
359
:
487
-491.
9
Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood.
2005
;
105
:
2640
-2653.
10
Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Blood.
2002
;
100
:
1014
-1018.
11
Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
N Engl J Med.
2003
;
348
:
2265
-2266.
12
Kreuzer KA, le Coutre P, Landt O, et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
Ann Hematol.
2003
;
82
:
284
-289.
13
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
N Engl J Med.
2002
;
346
:
645
-652.
14
Lange T, Bumm T, Otto S, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
Haematologica.
2004
;
89
:
49
-57.
15
Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
J Biol Chem.
2002
;
277
:
32214
-32219.
16
Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Blood.
2003
;
101
:
4611
-4614.
17
Deininger M, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells.
Blood.
1997
;
90
:
3691
-3698.
18
Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease.
Blood.
1998
;
92
:
3362
-3367.
19
Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification.
Clin Chem.
2000
;
46
:
1929
-1938.
20
Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Cell.
2003
;
112
:
831
-843.
21
Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy.
Science.
2001
;
293
:
2163
.
22
Leguay T, Desplat V, Barthe C, et al. Study of mutations in the ATP binding domain and the SH2/SH3 domain of BCR-ABL in 43 chronic myeloid leukemia patients treated by imatinib mesylate (STI571) [abstract].
Blood.
2003
;
100
:
369a
.
23
Deininger MW, McGreevey L, Willis S, et al. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Leukemia.
2004
;
18
:
864
-871.
24
Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.
J Biol Chem.
2000
;
275
:
24273
-24278.
25
Dierov J, Dierova R, Carroll M. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint.
Cancer Cell.
2004
;
5
:
275
-285.
26
Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
Blood.
1995
;
86
:
1148
-1158.
27
Amarante Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Blood.
1998
;
91
:
1700
-1705.
28
Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability.
Oncogene.
2002
;
21
:
8591
-8604.
29
Uribe-Luna S, Quintana-Hau JD, Maldonado-Rodriguez R, et al. Mutagenic consequences of the incorporation of 6-thioguanine into DNA.
Biochem Pharmacol.
1997
;
54
:
419
-424.
30
Hofmann WK, Komor M, Wassmann B, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Blood.
2003
;
102
:
659
-661.
31
Barnes DJ, Goldman JM, Melo JV. Dose-dependent effects of BCR-ABL on the phenotype of murine hematopoietic cells [abstract].
Blood.
2001
;
98
:
145a
.
32
Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood.
2003
;
102
:
276
-283.
33
Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Blood.
2004
;
104
:
2926
-2932.
34
Griswold IJ, Bumm T, O'Hare T, et al. Investigation of the biological differences between Bcr-Abl kinase domain mutations resistant to imatinib [abstract].
Blood.
2004
;
104
:
161a
.